Literature DB >> 17017004

Lower expression of p14ARF and p16INK4a correlates with higher DNMT3B expression in human oesophageal squamous cell carcinomas.

Tatiana de Almeida Simão1, Gabriela Loureiro De Bonis Almeida Simões, Fabiana Siqueira Ribeiro, Daniela Anhel de Paula Cidade, Nelson Adami Andreollo, Luiz Roberto Lopes, Jacyara Maria Brito Macedo, Rodolfo Acatauassu, Ana Maria Rossini Teixeira, Israel Felzenszwalb, Luis Felipe Ribeiro Pinto, Rodolpho Mattos Albano.   

Abstract

Oesophageal squamous cell carcinoma (ESCC) is one of the most common malignancies and is the sixth cause of cancer-related death in the world. Inactivation of cell-cycle regulating genes, such as p14ARF and p16INK4a, and cell adhesion genes, such as E-cadherin, is common in cancer, and results from genetic and/or epigenetic alterations. Therefore, we have analysed the mRNA expression of p14ARF, p16INK4a and E-cadherin in 17 matched ESCC and normal mucosal samples obtained from Brazilian patients by semi-quantitative RT-PCR. The expression of p14ARF and p16INK4a was absent or reduced in several ESCC samples. Hypermethylation of CpG islands, caused by the action of DNA methyltransferases (DNMTs), is a major form of epigenetic inactivation of the p14ARF and p16INK4a genes in tumours. Hence, we also investigated the mRNA expression of the human DNA methyltransferases in normal oesophageal mucosa and in the tumour matched samples. All DNMTs were constitutively expressed in the normal oesophageal mucosa but a significantly higher expression of DNMT3B was observed in the tumours. Data analysis by the Spearman rank test showed that the expression of DNMT3B was inversely correlated with that of p14ARF and p16INK4a. Our results suggest that DNMT3B over-expression may be involved in the suppression or lower expression of p14ARF and p16INK4a observed in ESCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17017004     DOI: 10.1191/0960327106het649oa

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  8 in total

1.  Genetic variation in the promoter of DNMT3B is associated with the risk of colorectal cancer.

Authors:  Qian Bao; Bangshun He; Yuqin Pan; Zhipeng Tang; Ying Zhang; Lili Qu; Yongfei Xu; Chan Zhu; Fuliang Tian; Shukui Wang
Journal:  Int J Colorectal Dis       Date:  2011-04-26       Impact factor: 2.571

2.  The DNMT3B -579 G>T promoter polymorphism and risk of lung cancer.

Authors:  Hui Liu; Yifei Jiao; Yana Guan; Yingbin Lao; Chengcheng Zhao; Hong Fan
Journal:  Exp Ther Med       Date:  2011-12-19       Impact factor: 2.447

3.  DNMT3B 579 G>T promoter polymorphism and risk of esophagus carcinoma in Chinese.

Authors:  Hong Fan; Dong-Sheng Liu; Shu-Hong Zhang; Jia-Bo Hu; Feng Zhang; Zhu-Jiang Zhao
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

4.  Associations of DNMT3B -149C>T and -2437T>A polymorphisms and lung cancer risk in Chinese population.

Authors:  Min Gao; Daqiang He; Fanji Meng; Jianing Li; Yan Shen
Journal:  World J Surg Oncol       Date:  2016-11-22       Impact factor: 2.754

5.  Inhibition of de novo Methyltransferase 3B is a Potential Therapy for Hepatocellular Carcinoma.

Authors:  Hong Fan; Jian Cheng; Zhu Jiang Zhao
Journal:  Gastroenterology Res       Date:  2008-11-20

Review 6.  Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes.

Authors:  Nair Lopes; Margareta P Correia; Rui Henrique; Carmen Jerónimo
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

7.  Promoter polymorphisms of DNMT3B and the risk of colorectal cancer in Chinese: a case-control study.

Authors:  Hong Fan; Feng Zhang; Jiabo Hu; Dongsheng Liu; Zhujiang Zhao
Journal:  J Exp Clin Cancer Res       Date:  2008-07-28

8.  Over-expression of HDAC8 down-regulate CDKN2A is associated with worse prognosis of esophageal squamous cell carcinoma.

Authors:  Effat Un Nesa; Xuan Chen; Cong Wang; Xue Chen; Yuan Wang; Yan Qu; Si Mi; Shanghai Guan; Fengxia Xiao; Yufeng Cheng
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.